Skip to main content
European Commission logo print header

NEFERTITI: A Novel Eco-Friendly, dually Efficient and Resistance-free Treatment of vaginITIs

Project description

A tablet for vaginal infections

The female genital tract is colonised by bacterial species such as lactobacilli which offer protection against various infections. However, bacterial or yeast infections are common and cause significant discomfort. Treatment involves the oral or topical administration of antibiotics or antifungals, but due to drug resistance, these regimens are not always successful, and infections recur. The EU-funded NEFERTITI project has developed a vaginal tablet for treating yeast and bacterial infections while keeping the vaginal microbiota intact. The tablet contains a natural substance that restores the normal pH in the vagina which is elevated during an infection. Treatment removes pathogenic microorganisms and reduces the risk of recurrent infections.

Objective

This project will develop a business plan to guide clinical validation and commercialization of pHyph, a novel treatment targeting vaginal yeast and bacterial infections.
Bacterial vaginosis (BV) and vulvovaginal candidiasis (VCC) are common vaginal infections caused by bacteria (often Gardnerella) or yeast (a fungus) called Candida. 450 million globally experience at least 4 vaginal bacteria or Candida infections each year. It causes significant discomfort, adversely affects quality of life and is associated with heavy socioeconomic burden. To date, all treatments are limited to antifungals and antibiotics that show low efficacy and high relapse rate. With prolonged usage, misdiagnosis, and overconsumption, there is a high incidence of drug resistance, which the WHO considered one of the biggest threats to global health.
Gedea has developed a vaginal tablet that contains the natural substance Glucono-δ-lactone (GDA), which switches Candida towards a benign yeast form, restores vaginal pH and disrupts the Candida and bacteria biofilm without causing treatment resistance. The yeast is removed through vaginal discharge. Since this is an antibiotic-free treatment, healthy bacteria that normally keep Candida at bay are also not removed and therefore a low relapse rate is expected with the use of pHyph. The product’s key feature lies in its ability to treat both yeast and bacterial infections and its use as both a preventative and curative treatment. These features are unmet by any other product on the market.
Preclinical research performed to date strongly supports pHyph’s novel mechanism to treat vaginal infections, reduce recurrent infections and eliminate the need for antibiotics/antimicrobials. The proposed project will further prepare pHyph for a clinical trial. SME Instrument funding will allow Gedea to close the gap on the road towards commercialisation.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

æ

Coordinator

GEDEA BIOTECH AB
Net EU contribution
€ 50 000,00
Address
Medicon village scheelevagen 2
223 81 Lund
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 21 429,00